OBJECTIVE: Puberty is part of a critical window in which adiposity and its correlates can be fine-tuned toward reproduction, which implies that puberty provides an opportunity to reprogram a misprogramming that occurred in early life. We tested this hypothesis in low-birthweight (LBW) girls with precocious pubarche (PP), who are at risk for hyperinsulinemic body adiposity during and beyond puberty. STUDY DESIGN:LBW girls with PP (n = 38; mean age 8 years) were randomized to remain untreated or to receive metformin across puberty (425 mg/d for 2 years, then 850 mg/d for 2 years); subsequently, all girls were monitored for 1 year without intervention. Here we report on the latter year. RESULTS: The benefits of metformin were mostly maintained during the posttreatment year so that, after 5 years, metformin therapy was associated with more lean mass; with less total, visceral, and hepatic fat; with lower circulating levels of androgens and leptin; and with elevated levels of high-molecular-weight adiponectin and undercarboxylated osteocalcin. CONCLUSION: In LBW girls with PP, pubertal metformin therapy was followed by a favorable adipokine profile and by a reduction of total, visceral, and hepatic adiposity beyond puberty.
RCT Entities:
OBJECTIVE: Puberty is part of a critical window in which adiposity and its correlates can be fine-tuned toward reproduction, which implies that puberty provides an opportunity to reprogram a misprogramming that occurred in early life. We tested this hypothesis in low-birthweight (LBW) girls with precocious pubarche (PP), who are at risk for hyperinsulinemic body adiposity during and beyond puberty. STUDY DESIGN: LBW girls with PP (n = 38; mean age 8 years) were randomized to remain untreated or to receive metformin across puberty (425 mg/d for 2 years, then 850 mg/d for 2 years); subsequently, all girls were monitored for 1 year without intervention. Here we report on the latter year. RESULTS: The benefits of metformin were mostly maintained during the posttreatment year so that, after 5 years, metformin therapy was associated with more lean mass; with less total, visceral, and hepatic fat; with lower circulating levels of androgens and leptin; and with elevated levels of high-molecular-weight adiponectin and undercarboxylated osteocalcin. CONCLUSION: In LBW girls with PP, pubertal metformin therapy was followed by a favorable adipokine profile and by a reduction of total, visceral, and hepatic adiposity beyond puberty.
Authors: Marta Díaz; Gemma Carreras-Badosa; Joan Villarroya; Aleix Gavaldà-Navarro; Judit Bassols; Francis de Zegher; Abel López-Bermejo; Francesc Villarroya; Lourdes Ibáñez Journal: Pediatr Res Date: 2022-07-11 Impact factor: 3.953
Authors: Jessica K Paulus; Christina D Williams; Furha I Cossor; Michael J Kelley; Robert E Martell Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-05 Impact factor: 4.254
Authors: Lourdes Ibáñez; Ken K Ong; Abel López-Bermejo; David B Dunger; Francis de Zegher Journal: Nat Rev Endocrinol Date: 2014-04-29 Impact factor: 43.330
Authors: Magdalena Kujawska-Luczak; Hanna Stankowiak-Kulpa; Ewelina Swora-Cwynar; Katarzyna Musialik; Paweł Bogdański; Joanna Suliburska; Marian Grzymisławski Journal: Prz Menopauzalny Date: 2014-05-21